Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;9(11):e104-e105.
doi: 10.1016/S2213-2600(21)00456-2. Epub 2021 Oct 20.

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

Pinkus Tober-Lau  1 , Tatjana Schwarz  2 , Kanika Vanshylla  3 , David Hillus  1 , Henning Gruell  4 ; EICOV/COVIM Study Group; Norbert Suttorp  1 , Irmgard Landgraf  5 , Kai Kappert  6 , Joachim Seybold  7 , Christian Drosten  2 , Florian Klein  8 , Florian Kurth  9 , Leif Erik Sander  10 , Victor Max Corman  2
Affiliations

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

Pinkus Tober-Lau et al. Lancet Respir Med. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

VMC is named together with Euroimmun on a patent application filed recently regarding the diagnosis of SARS-CoV-2 by antibody testing (application number EP20158626.0). HG and FKl are named on a patent application regarding neutralising antibodies against SARS-related coronaviruses (application number EP20177354). All other authors declare no competing interests. We thank all study participants at Charité – Universitätsmedizin Berlin for their participation. We also thank the entire staff of the Department for Occupational Medicine, the Charité Clinical Study Center at Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health (BIH) for their support during the study. SARS-CoV-2 RBD variant antigens were kindly provided by InVivo BioTech Services (Hennigsdorf, Germany) to the Seramun Diagnostica (Heidesee, Germany). Parts of this work were supported by grants from the BIH and Berlin University Alliance. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitätsmedizin zu COVID-19, (COVIM, FKZ: 01KX2021) to LES, FKu, FKI, CD, and VMC; through VARIPath projects (01KI2021) to VMC; and through Deutsche Forschungsgemeinschaft (SFB-TR84) to NS and LES. The study was supported by a donation from Zalando to Charité – Universitätsmedizin Berlin.

Figures

Figure
Figure
BNT162b2-induced SARS-CoV-2 antibody and T-cell response at 6-month follow-up in health-care workers and older people Health-care workers were enrolled at Charité - Universitätsmedizin Berlin (n=107) and older people were enrolled at an assisted living facility in Berlin, Germany (n=82). (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay. (B) Serum neutralisation titres (serum ID50) against the delta (B.1.617.2) VOC were measured 4 weeks after completion of the two-dose vaccine regimen with BNT162b2, and at the 6-month follow-up using a pseudovirus neutralisation assay. (C) SARS-CoV-2 S1-specific T-cell response detected by inteferon-γ release assay. Dotted horizontal lines indicate the manufacturer's threshold such as that for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and IQR, except for pNT, for which the geometric mean and 95% CI is shown. P values (all less than 0·0001) were calculated by the non-parametric Mann Whitney U test. ID50=50% inhibition dilution. IU=international units. pNT=pseudovirus neutralisation test. S/Co=signal-to-cutoff ratio. VOC=variant of concern.
See this image and copyright information in PMC

References

    1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed
    1. Thomas SJ, Moreira ED, Jr, Kitchin N, et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. 2021 doi: 10.1101/2021.07.28.21261159. published online July 28. (preprint) - DOI - PubMed
    1. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385–387. - PMC - PubMed
    1. Schwarz T, Tober-Lau P, Hillus D, et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerg Infect Dis. 2021;27:2174–2178. - PMC - PubMed
    1. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study. medRxiv. 2021 doi: 10.1101/2021.07.29.21261317. published online July 31. (preprint) - DOI - PMC - PubMed